<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Actinium Pharmaceuticals, Inc. (delaware) — News on 6ix</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware</link>
<description>Latest news and press releases for Actinium Pharmaceuticals, Inc. (delaware) on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/actinium-pharmaceuticals-inc-delaware" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d736a951cc36e47532e6c5.webp</url>
<title>Actinium Pharmaceuticals, Inc. (delaware)</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware</link>
</image>
<item>
<title>Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-announces-compelling-pan-tumor-data-for-atnm-400-demonstrating-broad-efficacy-across-prostate-lung-and-breast-cancer-models-at-the-2026-american-association-of-cancer-research-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-announces-compelling-pan-tumor-data-for-atnm-400-demonstrating-broad-efficacy-across-prostate-lung-and-breast-cancer-models-at-the-2026-american-association-of-cancer-research-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results for ATNM-400 across prostate, lung, and breast cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. ATNM-400 is a novel, first-in-class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that targets a non-PSMA membrane antigen overexpressed in adv</description>
</item>
<item>
<title>Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-announces-new-pan-tumor-preclinical-data-for-atnm-400-in-solid-tumors-and-differentiated-mechanism-for-actimab-a-in-aml-to-be-presented-at-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-announces-new-pan-tumor-preclinical-data-for-atnm-400-in-solid-tumors-and-differentiated-mechanism-for-actimab-a-in-aml-to-be-presented-at-2026-aacr-annual-meeting</guid>
<pubDate>Mon, 06 Apr 2026 11:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.</description>
</item>
<item>
<title>Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-present-two-abstracts-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Tue, 17 Feb 2026 12:42:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.</description>
</item>
<item>
<title>Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-presents-new-preclinical-data-demonstrating-potent-anti-tumor-activity-of-atnm-400-across-multiple-breast-cancer-subtypes-including-hormone-receptor-positive-triple-negative-and-tamoxifen-and-her2-therapy-resistant-breast-cancer-models-at-sabcs-2025</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-presents-new-preclinical-data-demonstrating-potent-anti-tumor-activity-of-atnm-400-across-multiple-breast-cancer-subtypes-including-hormone-receptor-positive-triple-negative-and-tamoxifen-and-her2-therapy-resistant-breast-cancer-models-at-sabcs-2025</guid>
<pubDate>Fri, 12 Dec 2025 13:45:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced the presentation of new preclinical data for ATNM-400, its first-in-class Actinium-225 (Ac-225) based antibody radioconjugate, at the 2025 San Antonio Breast Cancer Symposium (SABCS). The data highlight robust anti-tumor activity and a favorable tolerability profile across a broad panel of preclinical breast cancer models, including hormone receptor–positiv</description>
</item>
<item>
<title>Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-presented-at-the-san-antonio-breast-cancer-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-announces-atnm-400-data-demonstrating-potent-efficacy-in-triple-negative-breast-cancer-and-ability-to-overcome-endocrine-and-her2-targeted-therapy-resistance-being-presented-at-the-san-antonio-breast-cancer-symposium</guid>
<pubDate>Mon, 01 Dec 2025 13:45:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) antibody radioconjugate, in hormone receptor positive (HR+), HER2 positive (HER2+) and triple-negative breast cancer (TNBC) that will be presented at the San Antonio Breast Cancer Symposium (SABCS) being held December 10‑14, 2025 in San Antonio, Texas. The data demonstrates sig</description>
</item>
<item>
<title>Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-highlight-atnm-400-data-in-hormone-resistant-and-her2-resistant-breast-cancer-at-the-2025-san-antonio-breast-cancer-symposium-expanding-pan-tumor-profile-across-three-solid-tumor-indications</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-highlight-atnm-400-data-in-hormone-resistant-and-her2-resistant-breast-cancer-at-the-2025-san-antonio-breast-cancer-symposium-expanding-pan-tumor-profile-across-three-solid-tumor-indications</guid>
<pubDate>Tue, 04 Nov 2025 12:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody radioconjugate program, ATNM‑400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place December 10‑14, 2025 in San Antonio, Texas.</description>
</item>
<item>
<title>Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-participate-in-the-stephens-biotechnology-virtual-fireside-chat-conference</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-inc-to-participate-in-the-stephens-biotechnology-virtual-fireside-chat-conference</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens Biotechnology Virtual Fireside Chat. During the conference, members of Actinium's management team will also be available for one-on-one meetings with investors.</description>
</item>
<item>
<title>Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-announces-superior-anti-tumor-activity-of-atnm-400-in-lung-cancer-compared-to-the-leading-first-second-and-third-line-approved-egfr-mutant-therapies-and-mechanistic-synergy-with-osimertinib-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-announces-superior-anti-tumor-activity-of-atnm-400-in-lung-cancer-compared-to-the-leading-first-second-and-third-line-approved-egfr-mutant-therapies-and-mechanistic-synergy-with-osimertinib-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer (NSCLC). ATNM-400 a novel, multi-indication first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) is Actinium's lead solid tumor program, which is also being studied in prostate cancer. The data</description>
</item>
<item>
<title>Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-presents-new-data-demonstrating-potent-and-durable-efficacy-of-atnm-400-a-first-in-class-multi-tumor-actinium-225-radiotherapy-at-the-32nd-annual-prostate-cancer-foundation-scientific-retreat</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-presents-new-data-demonstrating-potent-and-durable-efficacy-of-atnm-400-a-first-in-class-multi-tumor-actinium-225-radiotherapy-at-the-32nd-annual-prostate-cancer-foundation-scientific-retreat</guid>
<pubDate>Fri, 24 Oct 2025 12:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA.</description>
</item>
<item>
<title>Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-to-unveil-the-multi-tumor-potential-of-atnm-400-a-first-in-class-actinium-225-radiotherapy-with-data-in-non-small-cell-lung-cancer-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-pharmaceuticals-to-unveil-the-multi-tumor-potential-of-atnm-400-a-first-in-class-actinium-225-radiotherapy-with-data-in-non-small-cell-lung-cancer-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</guid>
<pubDate>Mon, 13 Oct 2025 16:10:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC) has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22 – 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. ATNM-400 is a highly innovative, first-i</description>
</item>
<item>
<title>Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-to-present-atnm-400-preclinical-data-highlighting-durable-tumor-control-and-ability-to-overcome-resistance-to-standard-of-care-prostate-cancer-therapies-at-the-32nd-annual-prostate-cancer-foundation-scientific-retreat</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-to-present-atnm-400-preclinical-data-highlighting-durable-tumor-control-and-ability-to-overcome-resistance-to-standard-of-care-prostate-cancer-therapies-at-the-32nd-annual-prostate-cancer-foundation-scientific-retreat</guid>
<pubDate>Mon, 13 Oct 2025 12:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced that compelling preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225), has been accepted for presentation at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held on October 23 – 25, 2025 in Carlsbad, CA. The presentation</description>
</item>
<item>
<title>Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-presents-data-supporting-paradigm-changing-potential-of-atnm-400-in-prostate-cancer-demonstrating-its-superior-efficacy-and-improved-survival-in-treatment-resistant-tumor-models-versus-pluvicto-and-arpi-therapy-and-also-enhanced-efficacy-in-combination-with-arpi-therapy-at-the-4th-annual-targeted-radiopharmaceuticals-summit</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-presents-data-supporting-paradigm-changing-potential-of-atnm-400-in-prostate-cancer-demonstrating-its-superior-efficacy-and-improved-survival-in-treatment-resistant-tumor-models-versus-pluvicto-and-arpi-therapy-and-also-enhanced-efficacy-in-combination-with-arpi-therapy-at-the-4th-annual-targeted-radiopharmaceuticals-summit</guid>
<pubDate>Thu, 31 Jul 2025 12:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported additional preclinical data supporting its ATNM-400 radiotherapy prostate cancer candidate at the 4th Annual Targeted Radiopharmaceuticals Summit (TRP) being held July 29 – 31, 2025 in San Diego, CA. ATNM-400 is a novel, first-in-class targeted radiotherapy designed to deliver potent Actinium-225 (Ac-225), an alpha-emitter radioisotope, to prosta</description>
</item>
<item>
<title>Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-highlights-expanded-data-set-for-atnm-400-in-prostate-cancer-demonstrating-superior-efficacy-to-enzalutamide-and-ability-to-overcome-resistance-to-arpi-therapy-and-psma-ac-225lu-177-labelled-radiotherapy-at-the-society-of-nuclear-medicine-and-molecular-imaging-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-highlights-expanded-data-set-for-atnm-400-in-prostate-cancer-demonstrating-superior-efficacy-to-enzalutamide-and-ability-to-overcome-resistance-to-arpi-therapy-and-psma-ac-225lu-177-labelled-radiotherapy-at-the-society-of-nuclear-medicine-and-molecular-imaging-annual-meeting</guid>
<pubDate>Mon, 23 Jun 2025 15:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting being held June 21st – 24th, 2025, in New Orleans, Louisiana. The data prese</description>
</item>
<item>
<title>Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-announces-enrollment-of-first-patient-in-the-iomab-act-commercial-car-t-trial-at-the-university-of-texas-southwestern-medical-center</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-announces-enrollment-of-first-patient-in-the-iomab-act-commercial-car-t-trial-at-the-university-of-texas-southwestern-medical-center</guid>
<pubDate>Tue, 06 May 2025 12:45:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioni</description>
</item>
<item>
<title>Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-presents-data-showing-atnm-400-is-more-efficacious-than-pluvicto-and-is-highly-efficacious-after-pluvicto-resistance-in-prostate-cancer-tumor-models-at-the-american-association-for-cancer-research-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-presents-data-showing-atnm-400-is-more-efficacious-than-pluvicto-and-is-highly-efficacious-after-pluvicto-resistance-in-prostate-cancer-tumor-models-at-the-american-association-for-cancer-research-annual-meeting</guid>
<pubDate>Mon, 28 Apr 2025 12:30:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following tr</description>
</item>
<item>
<title>Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting</title>
<link>https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-highlights-mutation-agnostic-antileukemic-activity-of-actimab-a-against-flt3-npm1-kmt2a-and-tp53-mutations-in-aml-models-demonstrating-backbone-potential-for-acute-myeloid-leukemia-treatment-at-the-american-association-for-cancer-research-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinium-pharmaceuticals-inc-delaware/news/actinium-highlights-mutation-agnostic-antileukemic-activity-of-actimab-a-against-flt3-npm1-kmt2a-and-tp53-mutations-in-aml-models-demonstrating-backbone-potential-for-acute-myeloid-leukemia-treatment-at-the-american-association-for-cancer-research-annual-meeting</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including men</description>
</item>
</channel>
</rss>